Cerrahpaşa Medical Journal
ORIGINAL ARTICLE

Investigation of the Relationship Between TAFI Plasma Levels and Hemorrhage in Patients with Crimean-Congo Hemorrhagic Fever and the Role of TAFI in the Disease Pathogenesis

1.

Department of Infectious Disease, Adıyaman Training and Research Hospital, Adıyaman, Turkey

2.

Department of Infectious Disease, Atatürk University, Faculty of Medicine, Erzurum, Turkey

3.

Department of Medical Biochemistry, Atatürk University, Faculty of Medicine, Erzurum, Turkey

4.

Department of Public Health, Atatürk University, Faculty of Medicine, Erzurum, Turkey

5.

Department of Cardiology, Adıyaman Training and Research Hospital, Adıyaman, Turkey

Cerrahpasa Med J 2021; 45: 101-106
DOI: 10.5152/cjm.2021.21031
Read: 366 Downloads: 178 Published: 09 August 2021

Objective: Crimean-Congo hemorrhagic fever is a tick-borne viral infection presenting with fever and bleeding. Thrombin-activatable fibrinolysis inhibitor is a plasma procarboxypeptidase synthesized in the liver, causing downregulation of fibrinolysis. The association of thrombin-activatable fibrinolysis inhibitor levels with the clinical course and pathogenesis of Crimean-Congo hemorrhagic fever has not been adequately studied. The aim of the current study was to determine plasma thrombin-activatable fibrinolysis inhibitor levels in patients with Crimean-Congo hemorrhagic fever, and to reveal its role in the clinical course of the disease and in the pathogenesis of hemorrhage.

Methods: Forty-four patients diagnosed with Crimean-Congo hemorrhagic fever and 44 control subjects were included in the study. The diagnosis of Crimean-Congo hemorrhagic fever was based on a positive result for IgM antibodies or Crimean-Congo hemorrhagic fever virus detected by PCR. The thrombin-activatable fibrinolysis inhibitor levels were analyzed.

Results: The mean age and sex distribution were similar between the groups. The white blood cell, prothrombin time, activated partial thromboplastin time, and international normalized ratio values were also comparable (P > .05). The mean plasma thrombin-activatable fibrinolysis inhibitor value was 429.33 ± 328.224 ng/mL in the Crimean-Congo hemorrhagic fever group, and 922.44 ± 1236.449 ng/mL for the control group (P = .045).

Conclusion: Reduced thrombin-activatable fibrinolysis inhibitor levels were found in Crimean-Congo hemorrhagic fever patients. Decreased thrombin-activatable fibrinolysis inhibitor levels may contribute to the impairment of the coagulation mechanism. In other words, thrombin-activatable fibrinolysis inhibitor may be involved in the pathogenesis of bleeding in Crimean-Congo hemorrhagic fever.

Cite this article as: Şengül Aşkın H, Parlak M, Laloğlu E, Yılmaz S, Aşkın L, Parlak E. Investigation of the Relationship Between TAFI Plasma Levels and Hemorrhage in Patients with Crimean-Congo Hemorrhagic Fever and the Role of TAFI in the Disease Pathogenesis. Cerrahpaşa Med J. 2021;45(2):101-106.     

Files
TURKISH
EISSN 2687-1904